Apoptosis: Inhibitor or instigator of carcinogenesis?

Cancer Investigation

Volumn 14, Issue 5, 1996, Pages 455-465

  Manning, Francis C R ^a   Patierno, Steven R ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CARCINOGENESIS; DNA DAMAGE; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0029815880     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609018903     Document Type: Review

References (130)

1. Corcoran GB, Ray SD: The role of the nucleus and other compartments in toxic cell death produced by alkylating hepatotoxicants. Toxicol Appl Pharmacol 113:167-183, 1992.
2. Walker NI, Harmon BV, Kerr JFR: Patterns of cell death. Methods Arch Exp Pathol 13:144-159, 1988.
3. Kerr JF, Wyllie AH, Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-527, 1972.
4. Seale J, Kerr JFR, Bishop CJ: Necrosis and apoptosis: Distinct modes of cell death with fundamentally different significance. Pathol Ann 17:229-259, 1982.
5. Vaux DL: Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 90:786-789, 1993.
6. Raff MC: Social controls on cell survival and cell death. Nature 356:397-400, 1992.
7. Arends MJ, Morris RG, Wyllie AH: Apoptosis: The role of the endonuclease. Am J Pathol 136:593-608, 1990.
8. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68:251-306, 1980.
9. Kerr JFR, Harmon BV: Definition and incidence of apoptosis: An historical perspective. In: Apoptosis: The Molecular Basis of Cell Death, edited by LD Tomei, FO Cope. Plainview, NY, Cold Spring Harbor Press, 1991, pp 5-29.
10. Gerschenson LE, Rotello RJ: Apoptosis: A different type of cell death. FASEB J 6:2450-2455, 1992.
11. Booth C, Koch GLE: Perturbation of cellular calcium induces secretion of luminal ER proteins. Cell 59:729-737, 1989.
12. Compton MM: A biochemical hallmark of apoptosis: Internucleosomal degradation of the genome. Cancer Metast Rev 11:105-119, 1992.
13. Peitsch MC, Polzar B, Stephan H, et al: Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death). EMBO J 12:371-377, 1993.
14. Barry MA, Eastman A: Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. Arch Biochem Biophys 300:440-450, 1993.
15. 2+ and pH. Biochem Biophys Res Commun 186:782-789, 1992.
16. 2+ are not required to trigger apoptosis in human leukaemia cells. Clin Exp Immunol 87:465-471, 1992.
17. Rice WG, Hillyer CD, Harten B, et al: Induction of endonuclease-mediated apoptosis in tumor cells by C-nitroso-substituted ligands of poly(ADP-ribose) polymerase. Proc Natl Acad Sci USA 89: 7703-7707, 1992.
18. Negri C, Bernardi R, Braghelli A, et al: The effect of the chemotherapeutic drug VP-16 on poly(ADP)ribosylation in apoptotic HeLa cells. Carcinogenesis 14:2559-2264, 1993.
19. Venkatachalam S, Denissenko MF, Wani AA: Rapid activation of apoptosis in human leukemic cells by (+/-)-anti-benzo[a]pyrene diol epoxide induced DNA damage. Biochem Biophys Res Commun 197:722-729, 1993.
20. Ding R, Smulson M: Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: Influences on genomic stability, chromatin organization, and carcinogen cytotoxicity. Cancer Res 54:4627-4634, 1994.
21. Evans DL, Dive C: Effects of cisplatin on induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res 53:2133-2139, 1993.
22. Onishi Y, Azuma Y, Sata Y, et al: Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim Biophys Acta 1175, 147-154, 1993.
23. Dispasquale B, Youle RJ: Programmed cell death in heterokaryons. Am J Pathol 141:1471-1479, 1992.
24. Ghibelli L, Oliverio NS, Piacentini M, et al: Cycloheximide can rescue heat-shocked L cells from death by blocking stress-induced apoptosis. Exp Cell Res 201:436-443, 1992.
25. Lin J-K, Chou C-K: In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor β1. Cancer Res 52:385-388, 1992.
26. Forbes IJ, Zalewski PD, Giannakis C, et al: Induction of apoptosis in chronic lymphocytic leukemia cells and its prevention by phorbol ester. Exp Cell Res 198:367-372, 1992.
27. Blankenship LJ, Manning FCR, Orenstein JM, et al: Apoptosis is the mode of death caused by carcinogenic chromium. Toxicol Appl Pharmacol 126:75-83, 1994.
28. Manchester KM, Heston WDW, Donner DB: Tumour necrosis factor-induced cytotoxicity is accompanied by intracellular mitogenic signals in ME-180 human cervical carcinoma cells. Biochem J 290:185-190, 1993.
29. Bazar LS, Deeg HJ: Ultraviolet B-induced DNA fragmentation (apoptosis) in activated T-lymphocytes and Jurkat cells is augmented by inhibition of RNA and protein synthesis. Exp Hematol 20:80-86, 1992.
30. Ledda-Columbano GM, Coni P, Faa G, et al: Rapid induction of apoptosis in rat liver by cycloheximide. AmJ Pathol 140:545-549, 1992.
31. Collins RJ, Harmon BV, Souvlis T, et al: Effects of cycloheximide on B-chronic lymphocytic leukaemia and normal lymphocytes in vitro: Induction of apoptosis. Br J Cancer 64:518-522, 1991.
32. Martin SJ, Lennon SV, Bonham AM, et al: Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 145:1859-1867, 1990.
33. Song Q, Baxter GD, Kovacs EM, et al: Inhibition of apoptosis in human tumour cells by okadaic acid. J Cell Physiol 153:550-556, 1992.
34. Sarin A, Adams DH, Henkart PA: Protease inhibitors selectively block T cell receptor-triggered programmed cell death in a murine T cell hybridoma and activated peripheral T cells. J Exp Med 178:1693-1700, 1993.
35. Shi L, Kraut RP, Aebersold R, et al: A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med 175:553-566, 1992.
36. Jarvis WD, Koelsnick RN, Fornari FA, et al: Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA 91:73-77, 1994.
37. Obeid LM, Linardic CM, Karolak LA, et al: Programmed cell death induced by ceramide. Science 259:1769-1771, 1993.
38. Hannun YA, Linardic CM: Sphingolipid breakdown products: anti-proliferative and tumor suppressor lipids. Biochim Biophys Acta 1154:223-236, 1993.
39. Linardic CM, Jayadev S, Hannun YA: Brefeldin A promotes hydrolysis of sphingomyelin. J Biol Chem 267:14909-14911, 1992.
40. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins, and hyperthermia. Biochem Pharm 40:2353-2362, 1990.
41. Ijiri K: Apoptosis (cell death) induced in mouse bowel by 1,2-dimethylhydrazine, methylazoxymethanol acetate, and gamma radiation. Cancer Res 49:6342-6346, 1989.
42. Potten CS, Li YQ, O'Connor PJ, et al: A possible explanation for the differential cancer incidence in the intestine, based on distribution of the cytotoxic effects of carcinogens in the murine large bowel. Carcinogenesis 13:2305-2312, 1992.
43. Muschel RJ, Zhang HB, Iliakis G, et al: Cyclin B expression in HeLa cells during the G2 block induced by ionizing radiation. Cancer Res 51:5113-5117, 1991.
44. Warters RL: Radiation-induced apoptosis in a murine T-cell hybridoma. Cancer Res 52:883-890, 1992.
45. Hardin JA, Hinoshita F, Scherr DH: Mechanisms by which benzo[a]pyrene, an environmental carcinogen, suppresses B cell lymphopoiesis. Toxicol Appl Pharmacol 117:155-164, 1992.
46. Manning FCR, Blankenship LJ, Wise JP, et al: Induction of internucleosomal DNA fragmentation by carcinogenic chromate: Relationship to DNA damage, genotoxicity, and inhibition of macromolecular synthesis. Environ Health Perspect 102(Suppl 3:159-167), 1994.
47. Solary E, Bertrand R, Kohn KW, et al: Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 81:1359-1368, 1993.
48. Columbel M, Olsson CA, Ng P-Y, et al: Hormone-regulated apoptosis results from reentry of differential prostate cells into a defective cell cycle. Cancer Res 52:4313-4319, 1992.
49. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metast Rev 11:121-129, 1992.
50. Chromium, Nickel and Welding, IARC monographs on the evaluation of carcinogenic risks to humans. 49. Lyon, France, IARC, 1990.
51. The chromium problem: Research needs and risk assessment. Environ Health Perspect 92, Witmer, C., (Ed.) 1991.
52. Manning FCR, Xu J, Patierno SR: Transcriptional inhibition by carcinogenic chromate: Relationship to DNA damage. Mol Carcinogen 6:270-279, 1992.
53. 4 in synchronous and asynchronous cultured mammalian cells. Mol Pharmacol 29:606-613, 1986.
54. Sugiyama M, Wang XW, Costa M: Comparison of DNA lesions and cytotoxicity induced by calcium chromate in human, mouse, and hamster cell lines. Cancer Res 46:4547-4551, 1986.
55. Hamilton JW, Wetterhahn KE: Chromium (VI)-induced DNA damage in chick embryo liver and blood cells in vivo. Carcinogenesis 7:2085-2088, 1986.
56. Xu J, Wise JP, Patierno SR: DNA damage induced by carcinogenic lead chromate particles. Mutat Res 280:129-136, 1992.
57. Wise JP, Leonard JC, Patierno SR: Clastogenicity of lead chromate particles in hamster and human cells. Mutat Res 278:69-79, 1992.
58. Levy LS, Venitt S: Carcinogenicity and mutagenicity of chromium compounds: The association between bronchial metaplasia and neoplasia. Carcinogenesis 7:831-835, 1986.
59. Patierno SR, Banh D, Landolph JR: Transformation of C3H/ 10T1/2 mouse embryo cells to focus formation and anchorage independence by insoluble lead chromate but not soluble calcium chromate: Relationship to mutagenesis and internalization of lead chromate particles. Cancer Res 48:5280-5288, 1988.
60. Wise JP, Orenstein J-M, Patierno SR: Inhibition of chromate clastogenesis by ascorbate: Relationship to particle dissolution and uptake. Carcinogenesis 14:429-434, 1993.
61. Wise JP, Steams DM, Wetterhahn KE, et al: Cell-enhanced dissolution of carcinogenic lead chromate particles: The role of individual dissolution products in clastogenesis. Carcinogenesis 15:2249-2254, 1994.
62. Standeven AM, Wetterhahn KE: Ascorbate is the principal intracellular reductant of chromium(VI) in rat liver and kidney ultrafiltrates. Carcinogenesis 12:1733-1737, 1991.
63. De Flora S, Wetterhahn KE: Mechanisms of chromium metabolism and genotoxicity. Life Chem Rep 7:169-244, 1989.
64. Bridgewater LC, Manning FCR, Woo ES, et al: DNA polymerase arrest by adducted trivalent chromium. Mol Carcinogen 9:122-133, 1994.
65. Standeven AM, Wetterhahn KE: Is there a role for reactive oxygen species in the mechanism of chromium(VI) carcinogenesis? Chem Res Toxicol 4:616-625, 1991.
66. Jones P, Kortenkamp A, O'Brien P, et al: Evidence for the generation of hydroxyl radicals from a chromium(V) intermediate isolated from the reaction of chromate with glutathione. Arch Biochem Biophys 286:652-655, 1991.
67. Patierno SR, Blankenship LJ, Wise JP, et al: Genotoxin-induced apoptosis: Implications for Carcinogenesis. In: The Cell Cycle: Regulators, Targets, and Clinical Applications, edited by VH Hu. New York, Plenum Press, 1994, pp 331-340.
68. Xu J, Manning FCR, Patierno SR: Preferential formation and repair of chromium-induced DNA adducts and DNA-protein crosslinks in nuclear matrix DNA. Carcinogenesis 15:1443-1450, 1994.
69. Bridgewater LC, Manning FCR, Patierno SR: Base-specific arrest by carcinogenic chromium: Relationship to DNA interstrand crosslinking. Carcinogenesis, 15:2421-2427, 1994.
70. Sen S, D'Incalci M: Biochemical events and relevance to cancer chemotherapy. FEBS Lett 307:122-127, 1992.
71. Ledda-Columbano GM, Columbano A: Apoptosis and hepatocarcinogenesis. In: Apoptosis: The Molecular Basis of Cell Death, edited by LD Tomei, FO Cope. Plainview, NY, Cold Spring Harbor Press, 1991, pp 101-119.
72. Lin YQ, Fan CY, O'Connor PJ, et al: Target cells for the cytotoxic effects of carcinogens in the murine small bowel. Carcinogenesis 13:361-368, 1992.
73. Potten CS, Merrill A, Hickman J, et al: Characterization of radiation-induced apoptosis in the small intestine and its biological implications. Int J Radiat Biol 65:71-78, 1994.
74. Merritt AJ, Potten CS, Kemp CJ, et al: The role of p53 inspontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54:614-617, 1994.
75. Tomei LD, Kanter P, Wenner CE: Inhibition of radiation-induced apoptosis in vitro by tumor promoters. Biochem Biophys Res Commun 155:324-331, 1988.
76. Baxter GD, Lavin MF: Specific protein dephosphorylation in apoptosis induced by ionizing radiation and heat shock in human lymphoid tumor cells. J Immunol 148:1949-1954, 1992.
77. Hunter T: A thousand and one protein kinases. Cell 50:823-829, 1987.
78. Bursch W, Oberhammer F, Jirtle RL, et al: Transforming growth factor-β1 as a signal for induction of cell death by apoptosis. Br J Cancer 67:531-536, 1993.
79. Schulte-Hermann R, Timmermann-Trosiener I, Barthel G, et al: DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res 50:5127-5135, 1990.
80. Garcea R, Daino L, Pascale R, et al: Inhibition of promotion and persistent nodule growth by S-adenosyl-1-methionine in rat liver carcinogenesis: Role of remodeling and apoptosis. Cancer Res 49:1850-1856, 1989.
81. Bursch W, Paffe S, Putz B, et al: Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Carcinogenesis 11:847-853, 1990.
82. Cory S: Activation of cellular oncogenes in hematopoietic cells by chromosome translocation. Adv Cancer Res 47:189-234, 1986.
83. Vaux DL, Cory S, Adams JM: bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988.
84. Baffy G, Miyashita T, Williamson JR, et al: Apoptosis induced by withdrawal of interleukin-3(IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem 268:6511-6519, 1993.
85. Alnemri ES, Fernandes TF, Haldar S, et al: Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B-leukemias. Cancer Res 52:491-495, 1992.
86. Miyashita T, Reed C: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157, 1993.
87. Hockenberry D, Nunez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336, 1990.
88. Mah SP, Zhong LT, Liu Y, et al: The protooncogene bcl-2 inhibits apoptosis in PC12 cells. J Neurochem 60:1183-1186, 1993.
89. Garcia I, Martinou I, Tsujimoto Y, et al: Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science 258:302-304, 1992.
90. Korsmeyer SJ: bcl-2: An antidote to programmed cell death. Cancer Surv 15:105-118, 1992.
91. Williams GT: Programmed cell death: Apoptosis and oncogenesis. Cell 65:1097-1098, 1991.
92. Wagner AJ, Small MB, Hay N: myc-mediated apoptosis is blocked be ectopic expression of bcl-2. Mol Cell Biol 13:2432-2440, 1993.
93. Bissonnette RP, Echeverri F, Mahboubi A, et al: Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359:552-554, 1992.
94. Evan GI, Wyllie AH, Gilbert CS, et al: Induction of apoptosis in fibroblasts by c-myc protein Cell 69:119-128, 1992.
95. Reed JC, Haldar S, Croce CM, et al: Complementation by bcl2 and c-Ha-ras oncogenes in malignant transformation of rat embryo fibroblasts. Mol Cell Biol 10:4370-4374, 1990.
96. Miyashita T, Reed JC: bcl-2 transfer increases relative resistance of S491 and WEHI72 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407-5411, 1992.
97. Sinha AA, Blackard CE, Seal US: A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma. Cancer 40:2836-2850, 1977.
98. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
99. Levine AJ, Perry ME, Chang A, et al: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69:409-416, 1994.
100. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancer. Science 253:49-53, 1991.
101. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991.
102. Yonish-Rouach E, Resnitzky D, Lotem J, et al: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347, 1991.
103. Shaw P, Bovey R, Tardy S, et al: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89, 4495-4499, 1992.
104. Gerwin BI, Spillare E, Forrester K, et al: Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor β1. Proc Natl Acad Sci USA 89:2759-2763, 1992.
105. Oberhammer FA, Pavelka M, Sharma S, et al: Induction of apoptosis in cultured hepatocyles and in regressing liver by transforming growth factor β1. Proc Natl Acad Sci USA 89, 5408-5412, 1992.
106. Gottlieb E, Haffner R, von-Ruden T, et al: Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hemopoietic cells following IL-3 withdrawal. EMBO J 13:1368-1374, 1994.
107. Zhu YM, Bradbury DA, Russell NH: Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer 69:468-472, 1994.
108. Bates RC, Buret A, van-Helden DF, et al: Apoptosis induced by inhibition of intercellular contact. J Cell Biol 125:403-415, 1994.
109. Selvakumaran M, Lin HK, Miyashita T, et al: Immediate early regulation of bax expression by p53 but not TGF beta 1: A paradigm for distinct apoptotic pathways. Oncogene 9:1791-1798, 1994.
110. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994.
111. Korsmeyer SJ, Shutter JR, Veis DJ, et al: bcl-2/bax: A rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4:327-332, 1993.
112. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 74:957-967, 1993.
113. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994.
114. Clarke AR, Gledhill S, Hooper ML, et al: p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 9:1767-1773, 1994.
115. McCarthy SA, Symonds HS, Van-Dyke T: Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53. Proc Natl Acad Sci USA 91:3979-3983, 1994.
116. Livingstone LR, White A, Sprouse J, et al: Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 70:923-935, 1992.
117. Wyllie AH: Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview. Cancer Metas Rev 11:95-103, 1992.
118. Knight CRL, Rees RC, Griffin M: Apoptosis: A potential role for cytosolic transglutaminase and its importance in tumour progression. Biochim Biophys Acta 1096:312-318, 1991.
119. Rao L, Debbas M, Sabbatini P, et al: The adenovirus E1A proteins induce apoptosis which is inhibited by the E1B 19kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 89:7742-7746, 1992.
120. Lowe SW, Jacks T, Housman DE, et al: Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 91:2026-2030, 1994.
121. Luster MI, Blank JA, Dean JH: Molecular and cellular basis of chemically induced immunotoxicity. Annu Rev Toxicol 27:23-49, 1987.
122. Dean JH, Luster MI, Boorman GA, et al: Immune suppression following exposure of mice to the carcinogen benzo[a]pyrene but not the noncarcinogenic benzo[e]pyrene. Clin Exp Immunol 52: 199-206, 1983.
123. White KL Jr, Holsapple MP: Direct suppression of in vitro antibody production by mouse spleen cells by the carcinogen benzo[a]pyrene but not by the noncarcinogen cogener benzo[e]pyrene. Cancer Res 44:3388-3393, 1984.
124. Karimi M, Patierno SR, Manning FCR. Induction of apoptotic cell death by brefeldin A in human and hamster cells. Proc Am Assoc Cancer Res 36:36, 1995.
125. Zhan QTC, Fan S, Bae I, et al: Induction of box by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743-3751, 1994.
126. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995.
127. Boise LH, Gottschalk AR, Quintans J, et al. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Curr Topics Microbiol Immunol 200:107-121, 1995.
128. Craig RW. The bcl-2 gene family. Semin. Cancer Biol 6:35-43, 1995.
129. Knudson CM, Tung KS, Tourtellote WG, et al: tax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96-99, 1995.
130. Krajewski S, Blomquist C, Franssila K, et al. Reduced expression of poor response rates to combination chemotherapy and shorter survival in women with metastatic breast ademnocarcinoma. Cancer Res 55:4471-4478, 1995.